Premium
Modulation effect of catechin in angiogenesis and inflammation
Author(s) -
Negrão Rita,
Moura Liane,
Duarte Delfim,
Silva Rafael,
Soares Raquel
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.23.1_supplement.625.17
Subject(s) - angiogenesis , matrigel , chemistry , inflammation , tunel assay , umbilical vein , apoptosis , human umbilical vein endothelial cell , neovascularization , endothelial stem cell , chorioallantoic membrane , cell growth , in vivo , microbiology and biotechnology , pharmacology , immunology , biochemistry , in vitro , biology , cancer research
Inflammatory process is closely related to angiogenesis. Diets rich in plant‐derived polyphenols seem to protect from pathologies which present angiogenesis and inflammation in common. Catechin (Cat) is an abundant polyphenol. The aim of this study was to investigate the effect of Cat in angiogenesis and inflammation. Human umbilical vein endothelial cell (HUVEC) and human aortic smooth muscle cell (HASMC) were treated with 0.01‐100 µM Cat for 24 h. Cat increased viability (MTT) and decreased apoptosis (TUNEL) and proliferation (BrdU assay) in both cell lines. It decreased invasion capacity (double‐chamber assay) of HASMC while increasing it in HUVEC. Cat treatment led to a slight reduction in HASMC cell migration (injury assay) and increased HUVEC migration in the same conditions. Incubation of HUVEC on Matrigel‐coated plates with 10 µM Cat led to the formation of ramified cord‐like structures while 100 µM did not change the number of these structures. 100 µM Cat did not change the vessel sprouting capacity (aortic ring assay). Cat treatments diminished NO released to the extracellular medium but did not change the activity of NFkB. Cat interferes with some steps of angiogenic and inflammatory process but in vivo experiments are needed in order to confirm these properties. Supported by ERAB (EA0641), FCT (SFRH/BD/41888/2007) and iBeSa (BLSAD‐01/08, BLSAD‐2‐JUL/08)